Hundreds of Congress Attendees Run for Charity
July 11, 2017
More than 300 ISTH 2017 Congress attendees participated in the ISTH 2017 5K Charity Run/Walk on Tuesday night in Berlin’s Grunewald forest.
Read More
Final Results of RE-VERSE AD Study: Reversal of Dabigatran by its Specific Reversal Agent Idarucizumab in Patients with Uncontrolled Bleeding or Requiring Urgent Surgery/Procedures
July 11, 2017
Charles Pollack, M.D. presented the findings from the RE-VERSE AD study at Tuesday’s Late-Breaking Abstract Session.
Read More
Interim Results from a Phase 1/2 AAV5-FVIII Gene Transfer in Patients with Severe Hemophilia A
July 11, 2017
In a Late-Breaking Session on Tuesday, John Pasi, Ph.D., F.R.C.P., F.R.C.Path. revealed results of the first successful gene transfer in humans for the treatment of severe HA.
Read More
Novel Therapies for Hemophilia – Gene Therapy Replacement
July 11, 2017
During Tuesday’s State-of-the-Art Session “Novel Therapies for Hemophilia”, President and Chief Scientific Officer of Spark Therapeutics, Katherine High, M.D., Ph.D. summarized findings from their phase I/II trial of the long-term safety and efficacy of factor IX (FIX) gene therapy in patients with hemophilia B
Read More
Apply for an ISTH Training Fellowship to Gain Global Experience
July 11, 2017
If you wish to study at an institute known for their expertise in thrombosis and hemostasis, apply for an ISTH Training Fellowship
Read More
ISTH SSC 2018 President Dermot Cox Invites You to Dublin
July 11, 2017
Dermot Cox, Ph.D. previews next year’s 2018 ISTH SSC Congress that will take place in his hometown of Dublin, Ireland.
Read More